Recommendations for health care professionals
A table near the end of the document provides specific recommendations for health care professionals, including the following:
- Be knowledgeable about AID systems and nuances of different systems, including their distinguishing features as well as strengths and weaknesses.
- Inform patients with diabetes about AID systems, including review of currently available systems, and create realistic expectations for device use.
- Involve patients with diabetes in shared decision-making when considering use of AID systems.
- Share information with patients with diabetes, as well as their peers, about general standards set by national and international guidelines on AID systems.
- Provide an on-call number or method by which a person with diabetes can always access support from a health care provider at the practice, including weekends and nights.
- Implement, potentially, protocols on times when AID systems should not be used.
- Use an individual’s health data to improve quality of care and health outcomes.
Most members of the ADA/EASD Diabetes Technology Working Group work with industry, but industry had no input on the project. Dr. Sherr has reported conducting clinical trials for Eli Lilly, Insulet, and Medtronic, and has received in-kind support for research studies from Dexcom and Medtronic. She has also reported consulting for Eli Lilly, Lexicon, Medtronic, and Sanofi, and being an advisory board member for Bigfoot Biomedical, Cecelia Health, Eli Lilly, Insulet, T1D Fund, and Vertex Pharmaceuticals. Dr. Evans has reported conducting clinical trials or research collaborations for, serving on advisory boards for, or receiving speakers fees or travel support from Medtronic, Roche, Abbott Diabetes Care, Dexcom, Novo Nordisk, Eli Lilly, Sanofi, Zucara Therapeutics, Pila Pharma, and AstraZeneca. The University of Cambridge has received salary support for Dr. Evans from the National Health Service.
A version of this article first appeared on Medscape.com.